Northeast Pharmaceutical Group (SHE:000597) received approval to market raw drug material Efavirenz from the Chinese drug administration, according to a Shenzhen Stock Exchange disclosure on Saturday.
The approval is valid until Feb. 11, 2030.
Efavirenzis a key drug ingredient for the treatment of human immunodeficiency virus infection and a selective non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1), the pharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.